Jazz Pharmaceuticals to Take Over GW Pharmaceuticals for 7.2 Billion Dollars

UK: Medical Cannabinoids Jazz Pharmaceuticals to Take Over GW Pharmaceuticals for 7.2 Billion Dollars

04.02.2021Editor: Ahlam Rais

The global pharma company Jazz Pharmaceuticals has plans to acquire GW Pharmaceuticals, one of the leaders in developing cannabinoid-based medicines. The move is expected to attract many more investments into this sector.

The cannabis sector is still in the early phase of its growth to becoming a more mainstream Consumer and Healthcare category.
(Source: Pixabay)

UK – The Medical Cannabis and Wellness Ucits ETF is Europe’s first ETF focused on cannabis. The fund trades in London under CBDX and in Germany as CBSX and is passported for sale across Europe. It has focused on the medical side of Cannabis with pharmaceutical companies such as GW Pharma at the core of its portfolio – it accounts for around 14 % of the fund’s holdings.

Nawan Butt, Portfolio Manager of The Medical Cannabis and Wellness Ucits ETF, said: “GW Pharmaceuticals is a UK based company that made history by getting the first FDA approved drug derived from Cannabis. Their drug, Epidiolex has changed the lives of many living with epilepsy, and they are building out a platform looking at other areas. When they started most global pharma companies were hesitant to do work with this plant ignoring centuries of evidence that there were some health benefits. As times are changing and attitudes adjusting, more and more companies are getting involved with the sector. The traditional pharma company, Jazz pharma, has agreed to purchase GW Pharma for over 7 billion dollars. We don’t think this is the last deal we will see in the sector.”

China’s Pharmaceutical Equipment Market - Current Status, Trends and Recommendations for Action

As China is emerging as one of the world’s fastest-growing markets for the consumption of pharmaceuticals, it also offers huge opportunities for the global equipment industry.

This 40-page report aims to help you gain a better understanding of the current China's pharmaceutical market regarding a series of pharmaceutical industry related policies. Based on results of the survey among users in the pharmaceutical industry and the expert interviews, it will also provide you with a forecast for the industry and recommendations for your future operating and investment in China.

Butt continues, “One of the sectors that benefited the most from the US results was Cannabis. The sector is still in the early phase of its growth to becoming a more mainstream Consumer and Healthcare category and with the Democrats in power we expect the move towards legalization in the US to speed up. With this reality becoming more widely appreciated we have seen many of the US recreational focused cannabis names do extremely well over the past month. But now the focus of the sector could switch to the medical side. Today’s events should draw attention to other companies doing work in this sector and the opportunities they are exploring.”

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:47114034)